Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- 14-Day Prescription Limit Won’t Be Eased: MHLW
July 19, 2016
- Zyprexa under PMDA Review for Risk of Drug-Induced Hypersensitivity Syndrome
July 19, 2016
- CDISC Therapeutic Area Standards “Can Be Used in Japan”: MHLW Study Group
July 19, 2016
- Generics Should Vie on “Quality and Attractiveness”: MHLW Pharma Bureau Chief
July 15, 2016
- MHLW Pharma Bureau Chief Wants to Discuss Roles of Drug Makers’ 3 Key Officers
July 15, 2016
- Certified Review Boards Will Be Required “at Around 50 Institutions” if Clinical Research Bill Passes: MHLW Director
July 15, 2016
- MHLW to Request Budgets for AMED’s Project to Promote Commercialization of Innovative Medical Seeds
July 15, 2016
- More Companies Interested in Supporting Academia Research from the Seeds Stage: AMED Official
July 14, 2016
- MHLW to Set Prerequisites for Patients, Physicians to Optimize Innovative Drug Use: Pharma Bureau Chief
July 13, 2016
- Despite Brexit, Importance of UK “Will Remain Unchanged”: Dr Suematsu of AMED
July 12, 2016
- AMED Aims to Facilitate Drug Makers’ Access to Knowledge at Research Institutions: President
July 12, 2016
- PMDA Inks Comprehensive Collaboration Accord with NCNP
July 12, 2016
- MHLW to Put Expensive Drug Issue Up for Chuikyo Discussion ASAP: Medical Economics Division Chief
July 11, 2016
- “New Rules” for Expensive Drugs Could Impact Business Models: Health Insurance Bureau Chief
July 8, 2016
- Number of Academia-Originated Drugs Highest in Oncology: AMED Survey
July 7, 2016
- Imusera/Gilenya Don’t Delay Disability Progression in Primary Progressive MS, MHLW Orders Label Revisions
July 6, 2016
- MHLW OKs Sanofi’s PCSK9 Inhibitor, Other Drugs
July 5, 2016
- MHLW to Issue “Blue Book” on Quality of Generics by March-End
July 1, 2016
- It’s Now Up to UK Govt to Decide on Future Action after Brexit Vote: EMA Spokesperson
June 30, 2016
- MHLW Begins Interim Review of 10-Year Strategy on Hepatitis Research
June 29, 2016
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…